Tags

Type your tag names separated by a space and hit enter

[Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation].
Pol Merkur Lekarski. 2003 Jan; 14(79):36-8.PM

Abstract

The effectiveness and costs of azithromycin and cefoperazone treatment of COPD exacerbation have been analysed in this study. Forty patients at the mean age of 65.9 (+/- 11.5) years were enrolled. The subjects were randomly selected and treated either with cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons) or with azithromycin 1 x 0.5 g (group II = 20 persons), in sequential method. Body temperature, cough intensity, quality and quantity of expectorated sputum, number of breaths per minute and adverse events were recorded daily. The values of pulmonary function tests and leucocytosis were assessed three times during the study. Statistically significant differences between both groups have been found with respect to the mean time of staying in hospital (9.1 days--group I vs 6.1 days--group II), mean total duration of antibiotic therapy (10.1 days--group I vs. 6.6 days--group II) and duration of intravenous antibiotic therapy only [7.5 days (group I) vs 2.9 days (group II)] (p < 0.05). Taking into account the duration of hospitalization, it was shown that the mean total costs of treatment of COPD exacerbation with azithromycin was significantly lower than that of treatment with cefoperazone (2375.9 PLN and 1663.7 PLN, respectively) (p < 0.05).

CONCLUSIONS

The effectiveness of treatment with azithromycin in patients with COPD exacerbation was evident. The total costs of treatment of COPD exacerbation with azithromycin is lower than with cefoperazone. Both azithromycin and cefoperazone are safe in the treatment of exacerbation of COPD.

Authors+Show Affiliations

Klinika Chorób Wewnetrznych Pneumonologii i Alergologii, Centralnego Szpitala Klinicznego WAM w Warszawie.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Randomized Controlled Trial

Language

pol

PubMed ID

12712826

Citation

Faber, Małgorzata, et al. "[Comparative Analysis of the Effectiveness and Costs of Azithromycin and Cefoperazone Treatment of Patients During COPD Exacerbation]." Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego, vol. 14, no. 79, 2003, pp. 36-8.
Faber M, Jahnz-Rózyk K, Targowski T, et al. [Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. Pol Merkur Lekarski. 2003;14(79):36-8.
Faber, M., Jahnz-Rózyk, K., Targowski, T., & Mamełka, B. (2003). [Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego, 14(79), 36-8.
Faber M, et al. [Comparative Analysis of the Effectiveness and Costs of Azithromycin and Cefoperazone Treatment of Patients During COPD Exacerbation]. Pol Merkur Lekarski. 2003;14(79):36-8. PubMed PMID: 12712826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. AU - Faber,Małgorzata, AU - Jahnz-Rózyk,Karina, AU - Targowski,Tomasz, AU - Mamełka,Beata, PY - 2003/4/26/pubmed PY - 2003/7/8/medline PY - 2003/4/26/entrez SP - 36 EP - 8 JF - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego JO - Pol. Merkur. Lekarski VL - 14 IS - 79 N2 - UNLABELLED: The effectiveness and costs of azithromycin and cefoperazone treatment of COPD exacerbation have been analysed in this study. Forty patients at the mean age of 65.9 (+/- 11.5) years were enrolled. The subjects were randomly selected and treated either with cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons) or with azithromycin 1 x 0.5 g (group II = 20 persons), in sequential method. Body temperature, cough intensity, quality and quantity of expectorated sputum, number of breaths per minute and adverse events were recorded daily. The values of pulmonary function tests and leucocytosis were assessed three times during the study. Statistically significant differences between both groups have been found with respect to the mean time of staying in hospital (9.1 days--group I vs 6.1 days--group II), mean total duration of antibiotic therapy (10.1 days--group I vs. 6.6 days--group II) and duration of intravenous antibiotic therapy only [7.5 days (group I) vs 2.9 days (group II)] (p < 0.05). Taking into account the duration of hospitalization, it was shown that the mean total costs of treatment of COPD exacerbation with azithromycin was significantly lower than that of treatment with cefoperazone (2375.9 PLN and 1663.7 PLN, respectively) (p < 0.05). CONCLUSIONS: The effectiveness of treatment with azithromycin in patients with COPD exacerbation was evident. The total costs of treatment of COPD exacerbation with azithromycin is lower than with cefoperazone. Both azithromycin and cefoperazone are safe in the treatment of exacerbation of COPD. SN - 1426-9686 UR - https://www.unboundmedicine.com/medline/citation/12712826/[Comparative_analysis_of_the_effectiveness_and_costs_of_azithromycin_and_cefoperazone_treatment_of_patients_during_COPD_exacerbation]_ L2 - https://medlineplus.gov/copd.html DB - PRIME DP - Unbound Medicine ER -